Thank you for your presence here today.
In earlier testimony, we heard that there are very few adverse reactions reported and that the figure varied somewhere between 5 and 10%.
I am simply wondering whether the proposed clause 20.7 in Bill C-51, compelling health establishments to advise the minister of adverse reactions to drugs, may have a positive effect on the fact that few events are reported.
At the end of the day, will this provision make the process more effective and will the drugs that are available on the market have less of a chance of causing adverse reactions?